HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New drug combo aims to shrink tough head and neck tumors
Disease control OngoingThis study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effect…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody combo tested against hard-to-treat cancers
Disease control OngoingThis early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug duo aims to supercharge immunotherapy against head and neck cancer
Disease control OngoingThis study tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced head and neck cancer that has spread or come back. About 410 participants whose tumors have …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy plus precision radiation shows promise for Tough-to-Treat head and neck cancers
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to high-precision radiation (SBRT) can help people with head and neck cancer that has come back or is a new tumor in the same area. About 86 participants will receive either the combination o…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC